You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

You are here

MKSAP 19 "Quiz Me!" Question

Test your medical knowledge each month with questions from The Medical Knowledge Self-Assessment Program® (MKSAP).

MKSAP 19

For over 50 years, the Medical Knowledge Self-Assessment Program (MKSAP) has been the most trusted resource in continuous learning for internal medicine physicians and residents. The tradition continues with MKSAP 19.

MKSAP 19, released in early 2022, is available in several flexible formats, allowing you to choose the format that best fits your lifestyle. Each format includes 12 syllabus sections and 1,200 associated deep-learning self-assessment questions.

Learn about the new features in MKSAP 19, as well as pricing and release dates.

MKSAP 19 Q&A

A 32-year-old woman is evaluated for an asthma exacerbation. She previously had well-controlled asthma. She has increased the use of her maintenance inhaler and is using her rescue medication four times daily, but her symptoms persist. She reports no fever, chills, chest pain, or purulent sputum. She has no history of intubation, emergency department visits, or hospitalizations for asthma and has adhered to her medication regimen. She is a nonsmoker. Medications are inhaled budesonide and albuterol.

On physical examination, respiration rate is 25/min; the remainder of vital signs are normal. Oxygen saturation is 96% with the patient breathing ambient air. The patient is not using accessory muscles of respiration and is able to speak in full sentences. There is scattered expiratory wheezing.

Which of the following is the most appropriate treatment?

A: Doxycycline, 5-day course
B: Intravenous methylprednisone, followed by a 5-day prednisone course
C: Prednisone, 5-day course
D: Prednisone, 14-day course
E: Switch to budesonide-formoterol

Answer and Critique

Back to the October 2022 issue of ACP IMpact